BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31033499)

  • 21. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
    Pellerino A; Buffoni L; Rudà R; Soffietti R
    Neurology; 2019 Jul; 93(5):217-219. PubMed ID: 31248938
    [No Abstract]   [Full Text] [Related]  

  • 23. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
    Monzonís X; Arriola E
    J Thorac Oncol; 2019 Nov; 14(11):e247-e248. PubMed ID: 31668321
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brigatinib in
    Heredia D; Barrón F; Cardona AF; Campos S; Rodriguez-Cid J; Martinez-Barrera L; Alatorre J; Salinas MÁ; Lara-Mejia L; Flores-Estrada D; Arrieta O
    Future Oncol; 2021 Jan; 17(2):169-181. PubMed ID: 32986959
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
    Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of brigatinib for brain metastases in ALK fusion gene-positive non-small cell lung cancer: A case series.
    Morikawa K; Numata Y; Shinozaki Y; Kaneko S; Matsushima A; Nishida M; Kida H; Handa H; Nishine H; Mineshita M
    Thorac Cancer; 2024 Feb; 15(6):496-499. PubMed ID: 38158887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
    Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report.
    Li S; Zhang P; Wang T; Wang J; Duan J
    Thorac Cancer; 2021 Dec; 12(23):3273-3276. PubMed ID: 34647426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G; Tazza M; Matocci R; Chiari R; Crinò L
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
    BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
    Doménech M; Jové M; Aso S; Marín M; Nadal E
    Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
    Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients.
    Hochmair MJ; Prosch H; Krenbek D; Weinlinger C; Fabikan H; Valipour A
    Anticancer Drugs; 2021 Jan; 32(1):105-110. PubMed ID: 32868645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
    Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
    Meng Z; Li T; Wang P; Lizaso A; Huang D
    Cancer Biol Ther; 2021 Jan; 22(1):1-4. PubMed ID: 33380260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.